Galena Biopharma (GALE) - FREE Research Report

Schwartz Mark W. who is EVP & Chief Operating Officer at Galena Biopharma sold 100,000 shares at $5.57 on Jan. 31, 2014. Following this transaction, the EVP & Chief Operating Officer owned 409,665 shares meaning that the stake was reduced by 19.62% with the 100,000-share transaction.

The shares most recently traded at $4.48, down $1.08, or 24.22% since the insider transaction.

The average volume for Galena Biopharma has been 7.6 million shares per day over the past 30 days. Galena Biopharma has a market cap of $569.3 million and is part of the health care sector and drugs industry. Shares are up 9.07% year-to-date as of the close of trading on Friday.

Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing oncology treatments to address major unmet medical needs to advance cancer care. It is developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide. Currently there are 9 analysts that rate Galena Biopharma a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GALE - FREE

TheStreet Quant Ratings rates Galena Biopharma as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share. Get the full Galena Biopharma Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Tesoro Shares Rise on Better-Than-Expected Earnings

Marathon Petroleum Stock Could Surge -- Here's Why

Mad Money Lightning Round: Cramer Doesn't Want Health-Care Headaches

Jim Cramer's Mad Money: Keep One Eye on Earnings, the Other on Politics Next Week

Dow Off Highs as Crude Oil Makes Turn Lower